Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Rigel Pharmaceuticals clinical trials
The registry lists 28 studies whose lead sponsor is Rigel Pharmaceuticals. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 1, 2026.
Keep track of what changes. Save the Rigel Pharmaceuticals studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Rigel Pharmaceuticals.
- Rigel Pharmaceuticals28 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 28 of 28.
- Study of Olutasidenib and Temozolomide in HGGRecruitingNCT06161974Phase 2
- Olutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesRecruitingNCT07486713Phase 4
- Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)RecruitingNCT05308264Phase 1/2
- Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid TumorsRecruitingNCT07704658Phase 4
- A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaEnrolling by invitationNCT04138927Phase 3
- Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior TherapyTerminatedNCT04904276
- Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)CompletedNCT02077192Phase 3
- Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 SubjectsCompletedNCT04629703Phase 3
- A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHACompletedNCT03764618Phase 3
- A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)CompletedNCT02612558Phase 2
- Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) NephropathyCompletedNCT02112838Phase 2
- A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)CompletedNCT02076399Phase 3
- A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)CompletedNCT02076412Phase 3
- Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITPNo longer availableNCT03363334
- Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)CompletedNCT00665626Phase 2
- Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)CompletedNCT02040623Phase 2
- To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis SiccaCompletedNCT01900249Phase 2
- A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate AsthmaCompletedNCT01591044Phase 2
- Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell LymphomaCompletedNCT00798096Phase 2
- Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell LymphomaCompletedNCT00446095Phase 1/2
- Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid ArthritisCompletedNCT00665925Phase 2
- Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) LesionsCompletedNCT01597050Phase 2
- Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)CompletedNCT00706342Phase 2
- Open Label Study of Fostamatinib in the Treatment of IgA NephropathyWithdrawnNCT02433236Phase 2
- A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye DiseaseCompletedNCT01733992Phase 1
- Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus ErythematosusWithdrawnNCT00752999Phase 2
- Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)CompletedNCT00326339Phase 2
- 7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic RhinitisCompletedNCT00115089Phase 2